Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The trial of once-weekly exenatide demonstrated a directionally favorable effect on MACE but narrowly missed statistical significance.644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
In the citing paper
“In the Evaluation of Ertugli fl ozin Ef fi cacy and Safety CVOT (VERTIS CV), which recruited exclusively people with established CVD and type 2 diabetes, ertugli fl ozin was similar to placebo with respect to the primary MACE outcome and all key secondary outcomes (including a composite kidney outcome) except for HHF (146).”
In the citing paper
“While there was a trend for bene fi t for the key secondary endpoint of cardiovascular death or heart failure hospitalization, this did not meet statistical signi fi cance (HR: 0.88; 95% CI: 0.75 -1.03).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [91]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Food and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-77725 (https://www.govinfo.gov/content/pkg/FR-2008-12-19/pdf/E8-30086.pdf).
Cited by
Items 201–300 of 1,001
Qiu, M., Ding, L., Zhan, Z., & Liu, S.-Y. (2021) · Endocrine · doi:10.1007/s12020-021-02644-x · Cited by 49
“It could be associated with the fact that those meta-analyses failed to incorporate the data from the VERTIS CV trial [1] and the EMPERORReduced trial [6] since relevant data were not available.”
BackgroundMethodGiugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01213-w · Cited by 48
“Since then, other outcome trials have been published: specifically, the VERTIS-CV trial [35] with ertugliflozin (8246 patients with T2D randomized to ertugliflozin or placebo and followed for a mean of 3.5 years), the DAPA-HF trial [36, 37] with dapagliflozin (4744 patients with or without T2D and with HF randomized t…”
BackgroundMethodInfluentialNew Insights into the Use of Empagliflozin—A Comprehensive Review
Forycka, J., Hajdys, J., Krzemińska, J., Wilczopolski, P., Wronka, M., Młynarska, E., Rysz, J., & Franczyk, B. (2022) · Biomedicines · doi:10.3390/biomedicines10123294 · Cited by 63
SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
Mariani, M. V., Manzi, G., Pierucci, N., Laviola, D., Piro, A., D’Amato, A., Filomena, D., Matteucci, A., Severino, P., Miraldi, F., et al. (2024) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16344 · Cited by 52
Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease
Shaffner, J., Chen, B., Malhotra, D. K., Dworkin, L. D., & Gong, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.749010 · Cited by 52
SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
Podestà, M. A., Sabiu, G., Galassi, A., Ciceri, P., & Cozzolino, M. G. (2023) · Biomedicines · doi:10.3390/biomedicines11020279 · Cited by 63
“Similarly, the VERTIS CV trial, although successful on the primary cardiovascular outcome, failed to observe a significant effect of ertugliflozin on renal endpoints [36].”
ResultThe double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, M. T., de, A. P.-M., Julve, J., & Alonso, N. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02136-y · Cited by 55
“…of six CV and renal outcome trials of four SGLT2 inhibitors (empagliflozin [125], cana-gliflozin [126], dapagliflozin [127] and ertugliflozin [128]) in patients with T2D (EMPA-REG OUTCOME, CAN-VAS Programme, DECLARE-TIMI-58, CREDENCE, VERTIS CV) demonstrated a 32% reduction in HF…”
BackgroundPreventing diabetes complications
Templer, S., Abdo, S., & Wong, T. (2024) · Internal Medicine Journal · doi:10.1111/imj.16455 · Cited by 59
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
Dąbrowski, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041680 · Cited by 51
Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial
Cherney, D. Z. I., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Frederich, R. C., Maldonado, M., Liu, C., Liu, J., Pong, A., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01130121 · Cited by 51
Self-citationChadha, M. D., Das, A. K., Deb, P., Gangopadhyay, K. K., Joshi, S., Kesavadev, J., KOVIL, R. R., Kumar, S., Misra, A., & Mohan, V. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01219-x · Cited by 60
“EMPA-REG OUTCOME [58] (empagliflozin) CANVAS Program [59] (canagliflozin) DECLARE-TIMI 58 [60] (dapagliflozin) VERTIS CV [61] (ertugliflozin)”
Han, J., Luo, L., Wang, Y., Miyagishi, M., Kasim, V., & Wu, S. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01031-0 · Cited by 49
Becher, P. M., Schrage, B., Ferrannini, G., Benson, L., Butler, J., Carrero, J. J., Cosentino, F., Dahlström, U., Mellbin, L., Rosano, G. M. C., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2131 · Cited by 52
Self-citationSGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits
Leoncini, G., Russo, E., Bussalino, E., Barnini, C., Viazzi, F. C., & Pontremoli, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094441 · Cited by 49
“At variance with previous trials that have consistently shown renal protection through the use of SGLT2is, VERTIS CV (eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial) [57] reported that the use of ertugliflozin was not associated with a significant risk reduction in renal composite outcom…”
ResultLiu, H., Sridhar, V. S., Lovblom, L. E., Lytvyn, Y., Burger, D. E., Burns, K. D., Brinc, D., Lawler, P. R., & Cherney, D. Z. I. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.022 · Cited by 47
“Additionally, it is possible that ertugliflozin is not as effective as other SGLT2 inhibitors for reducing levels of proinflammatory and profibrotic factors, although this seems less likely based on similarities across the class for reducing the risk of hospitalization for heart failure and the risk of a sustained $40…”
BackgroundSelf-citationSGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
Adamczak, D., Ahmed, N., Tariq, H., Walgamage, M., WALGAMAGE, T., Mohammed, A., Chou, J. T.-T., Kałużna‐Oleksy, M., Lesiak, M., & Straburzyńska‐Migaj, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061470 · Cited by 55
“CANA, DAPA, EMPA, ERTU, and SOTA are recommended in T2DM patients at risk of CV events in order to reduce hospitalizations due to HF, MACE, ESRD, as well as CV death.”
MethodInfluentialPleiotropic effects of SGLT2 inhibitors and heart failure outcomes
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109927 · Cited by 48
Barbarawi, M., Al‐Abdouh, A., Barbarawi, O., Lakshman, H. G., kasasbeh, M. A., & Chen, K. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10083-z · Cited by 48
Pratley, R. E., Cannon, C. P., Cherney, D. Z. I., Cosentino, F., McGuire, D. K., Essex, M. N., Lawrence, D., Jones, P. L., Liu, J., Adamsons, I. A., et al. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00032-6 · Cited by 48
Self-citationKani, R., Watanabe, A., Miyamoto, Y., Ejiri, K., Iwagami, M., Takagi, H., Slipczuk, L. N., Tsugawa, Y., Aikawa, T., & Kuno, T. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031805 · Cited by 49
Wang, X., Ni, J., Guo, R., Li, L., Su, J., He, F., & Fan, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10096-8 · Cited by 49
Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease
Duan, S., Fang, L., Song, D., Zhang, C., Zhang, B., Xing, C., & Yuan, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.661185 · Cited by 50
Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
Gager, G. M., Gelbenegger, G., Jilma, B., von Lewinski, D., Sourij, H., Eyileten, C., Filipiak, K. J., Postula, M. A., & Siller-Matula, J. M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.691907 · Cited by 50
Song, Y., Huang, C., Sin, J., Germano, J. D. F., Taylor, D. J. R., Thakur, R., Gottlieb, R. A., Mentzer, R. M., & Andres, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010437 · Cited by 46
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population
Thorvaldsen, T., Ferrannini, G., Mellbin, L., Benson, L., Cosentino, F., McMurray, J. J. V., Dahlström, U., Lund, L. H., & Savarese, G. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.04.011 · Cited by 49
Self-citationConsensus statement on the current pharmacological prevention and management of heart failure
Sindone, A. P., Pasquale, C. G. D., Amerena, J. V., Burdeniuk, C., Chan, A., Coats, A. J. S., Hare, D. L., Macdonald, P. S., Sverdlov, A. L., & Atherton, J. J. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51656 · Cited by 48
Rodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-0772 · Cited by 49
Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
Chen, J., Pan, H., Shiao, C., Chuang, M., See, C. Y., Yeh, T.-H., Yang, Y., Chu, W.-K., & Wu, V. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02035-8 · Cited by 51
Monami, M., Candido, R., Pintaudi, B., Targher, G., & Mannucci, E. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.05.010 · Cited by 48
Wang, Y.-J., Paneni, F., Stein, S., & Matter, C. M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.755060 · Cited by 52
Lui, D. T. W., Au, I. C. H., Tang, E. H. M., Cheung, C., Lee, C., Woo, Y. C., Wu, T., Tan, K. C. B., & Wong, C. K. H. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101510 · Cited by 46
Segar, M. W., Kolkailah, A. A., Frederich, R. C., Pong, A., Cannon, C. P., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Liu, C., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14769 · Cited by 44
“The trial design, methodology and primary results of VERTIS CV have been previously described.(15,22) Briefly, VERTIS CV was a randomized, multicentre, double-blind trial that enrolled patients with T2DM and established atherosclerotic CV disease.”
MethodSelf-citationThe Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture
Dong, B., Lv, R., Wang, J., Che, L., Wang, Z., Huai, Z., Wang, Y., & Xu, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.918350 · Cited by 54
“Among the glucose-lowering agents, sodium–glucose co-transporter inhibitors (SGLT-2is) are highly recommended for patients with T2DM, especially those with a high cardiovascular or renal risk, due to their remarkable cardiorenal protective effects (3, 4).”
BackgroundSavarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Wang, A., Tang, H., Zhang, N., & Feng, X. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109080 · Cited by 44
Khunti, K., Jabbour, S. A., Cos, X., Mudaliar, S. R. D., Mende, C. W., Bonaca, M. P., & Fioretto, P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14684 · Cited by 45
“control, including cardiovascular and kidney protection.(11,38,51) Despite these benefits, therapeutic inertia among clinicians may play a role in the lack of uptake of this class of drugs, with many clinicians continu-”
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
SGLT2 inhibitors in people with and without T2DM
Khunti, K. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00453-2 · Cited by 43
Giugliano, D., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14374 · Cited by 48
Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin
Fontes‐Carvalho, R., Santos‐Ferreira, D., Raz, I., Marx, N., Ruschitzka, F. T., & Cosentino, F. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab034 · Cited by 50
Self-citationYuan, L., Li, F., Fan, Y., Yu, Y., Chen, M., & Xi, J. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.03.020 · Cited by 47
Nevola, R., Alfano, M., Pafundi, P. C., Brin, C., Gragnano, F., Calabrò, P., Adinolfi, L. E., Rinaldi, L., Sasso, F. C., & Caturano, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303106 · Cited by 49
“Reference [12] [13] [14] [15] [16] [17] [18]”
MethodRazuk, V., Chiarito, M., Cao, D., Nicolas, J., Pivato, C. A., Camaj, A., Power, D., Beerkens, F., Jones, D., Alter, A., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac001 · Cited by 41
Banerjee, M., Pal, R., Nair, K., & Mukhopadhyay, S. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.03.003 · Cited by 52
Rastogi, A., & Januzzi, J. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082824 · Cited by 42
“Data from EMPA-REG OUTCOME [14,63], DECLARE-TIMI 58 [18,69], DELIVER [25,30], VERTIS-CV [19,62], and CREDENCE [28,64] suggest that the early eGFR decrease should not be cause for concern unless there are signs and symptoms of volume depletion (orthostatic hypotension, blood pressure [BP] <120/70 mmHg), specifically in…”
BackgroundMethodInfluentialMousavi, A., Shojaei, S., Soleimani, H., Semirani-Nezhad, D., Ebrahimi, P., Zafari, A., Ebrahimi, R., Roozbehi, K., Harrison, A., Syed, M., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01635-6 · Cited by 44
Diallo, A., Carlos-Bolumbu, M., & Galtier, F. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101697 · Cited by 41
Papaetis, G. S. (2023) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/161170 · Cited by 41
Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Bradley, S., Spring, K. J., Beran, R. G., Chatzis, D., Killingsworth, M. C., & Bhaskar, S. M. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3495 · Cited by 44
Piepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab147 · Cited by 49
Zhou, B., Shi, Y., Fu, R., Ni, H., Gu, L., Si, Y.-X., Zhang, M., Jiang, K., Shen, J., Li, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.907340 · Cited by 43
“Araki 2016 Japan NCT02157298 HbA1c 7.2%–11%; INS ≥0.2 IU/kg/day and ≥15 IU/body/day for the past 8 weeks; additional treatment with DPP-4i and eGFR ≥45 ml/min/ 1.73m2 16 Dapagliflozin 5 mg + INS Placebo + INS Araki 2015 Japan NCT01368081 HbA1c 7.0%-10.0%; diet and exercise and monotherapy; no change background antidia…”
BackgroundInfluentialSarafidis, P., Papadopoulos, C. E., Kamperidis, V., Giannakoulas, G., & Doumas, M. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17005 · Cited by 39
Zheng, R.-J., Wang, Y., Tang, J.-N., Duan, J.-Y., Yuan, M.-Y., & Zhang, J.-Y. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001183 · Cited by 80
Muscoli, S., Barillà, F., Tajmir, R., Meloni, M., Della‐Morte, D., Bellia, A., Daniele, N. D., Lauro, D., & Andreadi, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081730 · Cited by 43
“5 years and who were randomly assigned to receive 5 mg or 15 mg of ertugliflozin or placebo [43].”
Cao, H., Rao, X., Jia, J., Yan, T., & Li, D. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01989-7 · Cited by 44
“Results from large randomized controlled trials (RCTs) showed that SGLT2 inhibitors could elicit protective effects against major CV and composite kidney events in patients with mild to moderate CKD, but only a few trials reported the application of SGLT2 inhibitors in patients with advanced CKD [9, 10]; as a result,…”
BackgroundJohansen, M. E., & Argyropoulos, C. (2020) · Clinical Cardiology · doi:10.1002/clc.23508 · Cited by 43
“The CVOTs reported to date include empagliflozin's EMPA-REG Outcome,(10) canagliflozin's integrated CANVAS Program(11) (comprised of two trials: CANVAS and CANVAS-R), dapagliflozin's DECLARETIMI-58(12) and ertugliflozin's VERTIS-CV.(13) The EMPA-REG OUTCOME trial,(10,14) demonstrated superiority of empagliflozin for t…”
MethodInfluentialTreatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations
Klen, J., & Dolžan, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189800 · Cited by 47
“In patients with albuminuria, ertugliflozin reduced the urine albumin/creatinine ratio (UACR), but the VERTIS-CV (eValuation of ERTUgliflozin Efficacy and Safety CardioVascular Outcomes) study did not observe significantly reduced composite renal endpoints compared to placebo [21,22].”
BackgroundOikonomou, E. K., Suchard, M. A., McGuire, D. K., & Khera, R. (2022) · Diabetes Care · doi:10.2337/dc21-1765 · Cited by 36
Self-citationBalogh, D. B., Wagner, L. J., & Fekete, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097789 · Cited by 38
A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
Liu, A. Y. L., Low, S. K., Yeoh, E. C. K., Lim, E. K., Renaud, C. J., Teoh, S. T. Y., Tan, G. F. L., Chai, C. C., Liu, B., Subramaniam, T., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac044 · Cited by 45
Jaiswal, A., Jaiswal, V., Ang, S. P., Hanif, M., Vadhera, A., Agrawal, V., Kumar, T., Nair, A. M., Borra, V., Garimella, V., et al. (2023) · Medicine · doi:10.1097/md.0000000000034693 · Cited by 42
“[11,13,19,20,27,28] The mean age of patients with SGLT2 inhibitors and the placebo group was 69.1 years and 69.37 years.”
BackgroundResultInfluentialUsman, M., Januzzi, J. L., Anker, S. D., Salman, A., Parikh, P. B., Adamo, M., Filippatos, G. S., Khan, M. S., Lala, A., Verma, S., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3129 · Cited by 40
Aggarwal, R., Bhatt, D. L., Szarek, M. J., Cannon, C. P., Leiter, L. A., Inzucchi, S. E., Lópes, R. D., McGuire, D. K., Lewis, J. B., Riddle, M. C., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00362-0 · Cited by 44
Self-citationCahn, A., Raz, I., Leiter, L. A., Mosenzon, O., Murphy, S. A., Goodrich, E. L., Yanuv, I., Rozenberg, A., Bhatt, D. L., McGuire, D. K., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2492 · Cited by 43
Self-citationChulián, S. G., Díaz‐Retamino, E., Testón, F. G., Gaitero, J. C., Castillo, M. J., Alfaro, R., Rodríguez, E., González-Caballero, E., & Martín-Santana, A. M. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02250-9 · Cited by 40
Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Tharmaraja, T., Ho, J. S. Y., Sia, C., Lim, N.-A., Chong, Y. F. V., Lim, A. Y. L., Rathakrishnan, R., Yeo, L. L. L., Sharma, V. K., & Tan, B. Y. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221086996 · Cited by 42
He, G., Yang, G., Huang, X., Luo, D., Tang, C., & Zhang, Z. (2023) · Heart & Lung · doi:10.1016/j.hrtlng.2023.02.009 · Cited by 44
Khunti, K., Aroda, V. R., Bhatt, D. L., Bozkurt, B., Buse, J. B., Heerspink, H. L., Inzucchi, S. E., Lam, C. S. P., Marx, N., McMurray, J. J. V., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14805 · Cited by 37
Lim, L.-L., Lau, E. S. H., Fu, A. W. C., Ray, S., Hung, Y.-J., Tan, A. T. B., Chamnan, P., Sheu, W. H. H., Chawla, M. S., Chia, Y.-C., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.7557 · Cited by 37
Lawler, P. R., Liu, H., Frankfurter, C., Lovblom, L. E., Lytvyn, Y., Burger, D. E., Burns, K. D., Brinc, D., & Cherney, D. Z. I. (2021) · Diabetes Care · doi:10.2337/dc20-2265 · Cited by 38
“Accordingly, this analysis examined the impact of treatment with an SGLT2 inhibitor, ertugliflozin, on markers of plasma volume contractionandmyocardial strain inparticipants with type 2 diabetes and moderate CKD.”
InfluentialSelf-citationDagogo-Jack, S., Pratley, R. E., Cherney, D. Z. I., McGuire, D. K., Cosentino, F., Shih, W. J., Liu, J., Frederich, R., Mancuso, J. P., Raji, A., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002484 · Cited by 37
Self-citationAlkabbani, W., Zongo, A., Minhas‐Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.12.005 · Cited by 45
Rao, S. D. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01989-z · Cited by 45
“The DECLARE-TIMI 58 (dapagliflozin), CANVAS (canagliflozin), EMPA-REG OUTCOME (empagliflozin), and VERTIS CV (ertugliflozin) CVOTs enrolled patients with T2D and established CVD and/or a broad range of CVD risk factors (Table 1) [10, 13, 14, 18].”
BackgroundLi, C. X., Liu, L. Y., Zhang, C. X., Geng, X. H., Gu, S. M., Wang, Y. Q., Liu, H., Xie, Q., & Liang, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1238399 · Cited by 46
“Diabetic ketoacidosis (2, 23, 54, 67, 113, 114, 118) SGLT-2is 7(3 register) was included in NMA 22295/15541 73(0.”
BackgroundInfluentialLiew, A., Lydia, A., Matawaran, B. J., Susantitaphong, P., Tran, H. T. B., & Lim, L. (2023) · Nephrology · doi:10.1111/nep.14167 · Cited by 42
The year in cardiovascular medicine 2020: heart failure and cardiomyopathies
Bueno, H., Moura, B., Lancellotti, P., & Bauersachs, J. K. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1061 · Cited by 44
“…empagliflozin and dapagliflozin reduce the risk of HF hospitalization regardless of baseline CV risk or history of HF. 101,102 In The VERTIS trial, ertugliflozin did neither significantly reduce CV events, nor the combined endpoint of CV death/HF hospitalization 103 but reduced HF hospitalizations.”
Zheng, C., Lin, M., Chen, Y., Xu, H., Yan, L., & Dai, H. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01272-z · Cited by 40
Täger, T., Frankenstein, L., Atar, D., Agewall, S., Frey, N., Grundtvig, M., Clark, A. L., Cleland, J. G. F., & Fröhlich, H. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01913-z · Cited by 39
A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease
Vecchio, L. D., Beretta, A., Jovane, C., Peiti, S., & Genovesi, S. (2021) · Drugs · doi:10.1007/s40265-021-01573-3 · Cited by 41
Zelniker, T. A., Wiviott, S. D., Mosenzon, O., Goodrich, E. L., Jarolím, P., Cahn, A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.0019 · Cited by 36
Self-citationButt, J. H., Kondo, T., Yang, M., Jhund, P. S., Docherty, K. F., Vaduganathan, M., Claggett, B. L., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad276 · Cited by 38
Pérez-Belmonte, L. M., Sanz-Cánovas, J., García de Lucas, M. D., Ricci, M., Avilés-Bueno, B., Cobos-Palacios, L., Pérez-Velasco, M. A., López-Sampalo, A., Bernal-López, M. R., Jansen-Chaparro, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851035 · Cited by 35
Nephrotic Syndrome: From Pathophysiology to Novel Therapeutic Approaches
Frățilă, G., Lupusoru, G. E., Sorohan, B. M., Obrișcă, B., Mocanu, V., Lupușoru, M. O. D., & Ismail, G. (2024) · Biomedicines · doi:10.3390/biomedicines12030569 · Cited by 51
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 70
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
Xiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 37
“Other SGLT2 inhibitors The VERTIS-CV (Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes) trial [24], which recruited patients with T2DM and established ASCVD, showed that ertugliflozin, as compared with placebo, only reduced the risk of hospitalization for HF, without significant reduction in ris…”
BackgroundMethodInfluentialSciacqua, A., Succurro, E., Armentaro, G., Miceli, S., Pastori, D., Rengo, G., & Sesti, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10182-x · Cited by 38
Teo, Y. N., Ting, A. Z. H., Teo, Y. H., Chong, E. Y., Tan, J. T. A., Syn, N. L. X., Chia, A. Z. Q., Ong, H. T., Cheong, A. J. Y., Li, T. Y., et al. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00528-7 · Cited by 41
Osto, E., Bonacina, F., Pirillo, A., & Norata, G. D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106667 · Cited by 40
Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
Ntentakis, D. P., Correa, V., Ntentaki, A. M., Delavogia, E., Narimatsu, T., Efstathiou, N. E., & Vavvas, D. G. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06236-5 · Cited by 43
Kunutsor, S. K., Khunti, K., & Seidu, S. (2023) · Journal of the Royal Society of Medicine · doi:10.1177/01410768231198442 · Cited by 39
Diallo, A., Carlos‐Bolumbu, M., & Galtier, F. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02154-4 · Cited by 38
Iordan, L., Gaiţă, L., Timar, R. Z., Avram, V. F., Sturza, A., & Timar, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137057 · Cited by 37
McLean, P., Bennett, J., Woods, E. A., Chandrasekhar, S. A., Newman, N. A., Mohammad, Y., Khawaja, M., Rizwan, A. M., Siddiqui, R., Birnbaum, Y., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00068-z · Cited by 46
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
O’Donoghue, M. L., Kato, E. T., Mosenzon, O., Murphy, S. A., Cahn, A., Herrera, M., Tankova, T. I., Šmahelová, A., Merlini, P. A., Gause‐Nilsson, I. A. M., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05399-2 · Cited by 34
“Nonetheless, the DECLARE-TIMI 58 trial was the largest of the Phase III trials of an SGLT2 inhibitor in type 2 diabetes [10, 13, 14].”
MethodSelf-citationSim, R., Chong, C. W., Loganadan, N. K., Fong, A. Y. Y., Navaravong, L., Hussein, Z. B., Khunti, K., & Lee, S. W. H. (2021) · Diabetic Medicine · doi:10.1111/dme.14780 · Cited by 37
Lin, D. S., Yu, A., Lo, H.-Y., Lien, C.-W., Lee, J., & Chen, W. (2022) · Diabetologia · doi:10.1007/s00125-022-05772-9 · Cited by 40
Use of Glucose-Lowering Agents in Diabetes and CKD
Alicic, R. Z., Neumiller, J. J., Galindo, R. J., & Tuttle, K. R. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.09.018 · Cited by 38
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
Li, H., Tse, Y.-K., Chandramouli, C., Hon, N. W. L., Cheung, C., Lam, L.-Y., Wu, M., Huang, J.-Y., Yu, S.-Y., Leung, K. L. C., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac558 · Cited by 36
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease
Solomon, J., Festa, M. C., Chatzizisis, Y. S., Samanta, R., Suri, R. S., & Mavrakanas, T. A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108330 · Cited by 37
Metadata
- Authors
- Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., Shih, W. J., Gantz, I., Terra, S. G., Cherney, D. Z. I., & McGuire, D. K.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-08
- Volume
- 383
- Issue
- 15
- Pages
- 1425-1435
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3089283105
- Cited by
- 1,514
- References
- 14
- Citations by year
- 2026: 126 · 2025: 177 · 2024: 231 · 2023: 269 · 2022: 298 · 2021: 364 · 2020: 47
- FWCI
- 184.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Pfizer
- Merck
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- ertugliflozin, SGLT2 inhibitors, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, non-inferiority, renal safety, non-inferiority margin, myocardial infarction, stroke, renal replacement therapy, serum creatinine doubling, cardiovascular risk stratification
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Placebos, Bridged Bicyclo Compounds, Heterocyclic, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.